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Objective. There are limited data on the changes of treatment strategies of disease-modifying drugs used to treat pediatric inflam-
matory bowel disease (IBD). Methods. We utilized data from two national registers: the Drug Reimbursement Register for drug
costs (for identifying children with IBD) and the Drug Purchase Register (for exposure to drugs), both of which are maintained
by the Social Insurance Institution of Finland. The frequencies and trends of drug therapy strategies during the first year of
pediatric IBD were evaluated between 1999 and 2009. Results. A total of 481 children diagnosed with IBD were identified. During
the first sixmonths, 68% of the patients purchased systemic corticosteroids; these combined with 5-aminosalicylic acid in almost all
cases. The use of corticosteroids was stable from the early years compared with the end of the study period. In Crohn’s disease, there
was a trend towards more active use of azathioprine: the therapy was introduced earlier and proportion of pediatric patients
purchasing azathioprine increased by up to 51% (P < 0.05). Conclusions. In pediatric IBD, the majority of patients purchased
corticosteroid within the first six months, reflecting moderate-to-severe disease. During recent years in pediatric Crohn’s disease,
the therapeutic strategies of oral medication have changed towards more active immunosuppression with azathioprine.
1. Introduction
An increase in the incidence of pediatric inflammatory bowel
disease (IBD), namely, Crohn’s disease and ulcerative colitis
(UC), has recently been observed inmanyWestern countries,
including the Nordic countries [1–4]. It has been estimated
that there are about 1–1.5 million patients with IBD in the
United States. The prevalence of pediatric IBD being approx-
imately 71 per 100, 000 the treatment of this disease burdens
significantly the health care [5, 6]. Medical specialists agree
that the pediatric form of the disease has a more aggressive
disease course than IBD in adults [7]. This is reflected in
the high use of corticosteroids and in the high frequency of
surgeries [8]. There is, however, no evidence that the disease
phenotype has changed along with increasing incidence of
the disease. In many countries, most pediatric patients have
Crohn’s disease [3], but in Finland UC is about twice as
common as Crohn’s disease [4]. In children, Crohn’s disease
in most cases aﬀects the colon and it is uncommon for the
disease to be limited to the upper gastrointestinal tract or to
the small intestine only [9].
The recent guidelines for treating pediatric Crohn’s
disease [10] or UC [11, 12] are mainly based on data extrap-
olated from adult studies [13–15]. Of the immunomodu-
lators, azathioprine is used most often, whereas the use of
methotrexate has been limited [16]. The use of the TNF-α
antagonist agent infliximab has been approved for moderate-
to-severe Crohn’s disease in children older than six years of
age in 2006 and restricted to hospital use. Infliximab was
approved for clinical use in pediatric UC in 2011 but not
yet in younger children. The other TNF-α antagonist agent,
adalimumab, has been used for study purposes [17, 18],
but, likewise, it has not yet been approved for clinical use
in pediatric IBD. There has been, however, lively discussion
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on whether or not IBD therapy should be shifted towards
more active immunosuppression by the time of diagnosis to
ensure a complication-free disease course [19, 20] but so far
there is no clear consensus on the criteria for introducing
immunomodulators at an early phase of pediatric IBD. It is
possible, however, that the therapeutic strategies of pediatric
IBD have begun using immunomodulation more widely.
Likewise, it is unclear whether the availability of TNF-α
antagonists has changed the pattern of therapeutic strategies.
This is important to assess for the future when the impact
of immunosuppression on the long-term prognosis of the
pediatric patients will be an important issue.
Here, we used the opportunity to study drug purchases
in pediatric IBD patients during the first year after diagnosis
using nationwide data from comprehensive registers. We
studied trends in treatment strategies between 1999 and 2009
and in the periods of 1999-2005, 2006–2007 and 2008-2009.
2. Subjects and Methods
2.1. Data Sources. In Finland, all IBD patients, irrespective
of the place of residence and the socioeconomic status of the
family, are entitled to special refunds governed by the Social
Insurance Institution of Finland (Kela) to cover part of the
medical costs. Kela processes drug reimbursements accord-
ing to a written certificate describing the diagnostic criteria
for IBD (ICD-10 code K50 or K51) signed by a specialist
in pediatrics and/or gastroenterology. The certificates are
checked by amedical examiner (physician) before Kela grants
the reimbursement. Rejections are exceptional, particularly
for children, and reimbursements are included in the routine
care of the patients. Using the Drug Reimbursement Register,
we identified 481 Finnish children aged 0–15 years born
between 1 January 1994 and 31 December, 2008 who had
been diagnosed with IBD by 30 September, 2009. Kela’s
administrative process takes only a couple of weeks. There-
fore, the date of the special refund decision was defined as
the index date of diagnosis.
We identified drug purchases, a proxy indicator for
outpatient drug use during the first year after receiving a
diagnosis (followup until September 2010), using the nation-
wide Drug Purchase Register, which lists drugs according
to the World Health Organization’s Anatomical Therapeutic
Chemical (ATC) Classification System. The register covers
outpatient drug purchases in pharmacies but not the use of
such drugs in hospitals. Thus, we could not trace the use of
the TNF-α-antagonist agent infliximab and, because adali-
mumab is not yet licensed for pediatric patients, it is rarely
used in children. The oral medications included corticos-
teroids, sulfasalazine, 5-aminosalicylic acid (5-ASA), prepa-
ration mesalazine, azathioprine, methotrexate, locally active
corticosteroids, local 5-ASA preparations and the antimi-
crobials: metronidazole and ciprofloxacin. According to the
Finnish regulations on reimbursement, the maximum num-
ber of tablets supplied covers a three-month period. Thus,
most patients purchase the drugs used for maintenance
medication more than once a year. We studied trends in
therapeutic strategies between 1999 and 2009 for the whole
study period and for three specific periods of time: 1999–
2005, 2006–2007 and 2008–2009.
2.2. Statistical Analyses. We used logistic and linear regres-
sion analyses when studying the purchases made by the
groups of patients with Crohn’s disease and UC or those
made during diﬀerent time periods. As the mean ages of the
patients increased towards the end of the study period (with
the groups for the years 2006–2007 and 2008–2009 being
slightly older than the group for the years 1999–2005), we
analyzed the associations between the time periods after
adjusting them to account for the diﬀerences in age. The sta-
tistical significance was set at the 5% level (two-sided). The
statistical analyses were performed using the SAS system for
Windows (version 9.2 SAS Institute Inc., Cary, NC, USA).
2.3. Ethics. The ethical committee of Kela’s Research Depart-
ment approved the study protocol. In accordance with
Finnish regulations, no informed consent is required for
registry-based studies in which no contact has been made
with the subjects of the study.
3. Results
Between 1999 and 2009, we identified a total of 481 children
aged 0–15 years with newly diagnosed IBD (incident cases).
Of these, 293 had UC and 188 had Crohn’s disease. At the
onset of disease, the mean age of the patients with UC was
7.9 years (SD 3.9), significantly lower than for those with
Crohn’s disease (9.3± 3.9 years, P < 0.001). The majority of
the patients were boys: 64% of patients with Crohn’s disease
and 52% of patients with UC (P = 0.010).
During the first 12 months of the disease, 5-ASA and
corticosteroids (both for the systemic use) were the two
drugs that patients purchased the most throughout the entire
study period (1999-2009). 5-ASA was used with comparable
frequencies for Crohn’s disease (93%; Table 1) and for UC
(94%; Table 2). The proportion of 5-ASA users increased
linearly (P = 0.040) up to 96% for Crohn’s disease in 2008–
2009. Accordingly, the proportion of 5-ASA users with UC
increased towards the end of the study period from 89%
between 1999 and 2005 to 97% between 2008 and 2009 (P =
0.028; Table 2). Nearly 75% of IBD patients purchased oral
corticosteroids without any significant diﬀerence between
the subtypes of diagnoses, (Tables 1 and 2). As a rule, cor-
ticosteroids were introduced by the time of the diagnosis and
only 4.5% of the first-year users made their first purchases
more than six months after the diagnosis. The frequency
of corticosteroid use stayed constant during the seven-year
period (between 1999 and 2005) and the last two years of the
study period (2008 and 2009) (Tables 1 and 2).
Few of the patients with Crohn’s disease (20%) purchased
locally active therapeutic agents (5-ASA or corticosteroids),
whereas nearly half of the UC patients (48%) purchased such
agents (P < 0.001, age adjusted; Tables 1 and 2). During
the first 12 months, the use of two antimicrobials metron-
idazole and/or ciprofloxacin targeted at microbiota in the
gastrointestinal tract was more frequent among patients with
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Crohn’s disease (47%) than among UC patients (31%, P =
0.009, age adjusted). Both groups used the drug metro-
nidazole most frequently, using it nearly twice as frequently
as ciprofloxacin.
During the first 12months of the disease, themost widely
used immunomodulator was azathioprine. Its use was more
frequent among patients with Crohn’s disease (43%) than
among UC patients (30%; P = 0.037, age adjusted; Tables 1
and 2). With Crohn’s disease, there was a significant linear
trend (P = 0.030) to more frequent use of azathioprine over
the three study periods (1999-2005, 2006-2007 and 2008-
2009), with it reaching 51% for patients diagnosed in 2008–
2009 (Table 1). Such an increase in use was not observed
in patients with UC; among UC patients, the proportion of
users was 35% during the last study period (2008-2009),
which was significantly less than for those with Crohn’s dis-
ease (P = 0.033, age adjusted; Tables 1 and 2).
There was also a significant diﬀerence in the time inter-
vals from the diagnosis to the introduction of azathioprine:
during the first 12 months after diagnosis, azathioprine was
introduced approximately one month earlier to patients with
Crohn’s disease (113 days) than to those with UC (mean 153
days, P = 0.035, age adjusted). Moreover, for patients with
Crohn’s disease these time intervals decreased towards the
end of the study period: the first purchases occurred at a
mean of 160 days after diagnosis between the years 1999 and
2005, 123 days between the years 2006 and 2007, and 98 days
between the years 2008 and 2009 (P for linear trend 0.057).
For patients with UC, the corresponding figures were 148,
161, and 146 days. The use of methotrexate was rare.
During the first year after the diagnosis, the purchases of
biologic agent for outpatient use were infrequent; in 2008–
2009 only three children with Crohn’s disease purchased
adalimumab. During the first year of the disease, there were
no purchases of mercaptopurine, cyclosporine, tacrolimus or
mycophenolate. All of the children purchased some drugs
during the first six months, and only 4.2% of patients
(Crohn’s disease n = 9; UC n = 11) made no purchases
between 7 and 12 months.
The early (up to the first six months) drug therapy strate-
gies, whether as a single therapy or a combination of thera-
pies, are shown in Table 3. During the first six months, there
was a significant linear trend (P = 0.027) over the three
study periods towardsmore active use of azathioprine among
patients with Crohn’s disease, but not among patients with
UC. The strategies for IBD pharmacotherapy were associated
with the subtype of diagnosis, with the age of the patient
at the time of the diagnosis, and with the later years of the
patient during the study period (Table 4). Azathioprine was
more often prescribed to older patients than 5-ASA. Gender
had no significant eﬀect on the pharmacotherapy strategies.
4. Discussion
We presented here nationwide, register-based data on the
purchases of therapeutic agents by patients with pediatric
IBD in Finland during the first year of diagnosis throughout
the first decade of the twenty-first century. There are no
equally comprehensive reports on the practice of medical
management and its changes in pediatric IBD. Clinical
guidelines for the treatment of pediatric IBD are sparse [10,
11, 21]; based on limited evidence [12], and the types of ther-
apies vary widely. Among patients recently diagnosed with
Crohn’s disease, there are statistically significant variation
in initial management between diﬀerent specialist clinics,
as is evident in examples from the United States [22]. Our
results show that the use of azathioprine in pediatric Crohn’s
disease has become more commonplace. Most patients were
introduced to corticoids within three months of the diagno-
sis and we observed no significant changes in the proportion
of patients purchasing corticoids. Although the nationwide
use of the TNF-α antagonist infliximab could not be eval-
uated here, it seems that its availability has not markedly
influenced the strategies of the early medical management of
pediatric IBD.
5-ASA was the most widely used outpatient therapeutic
agent for patients with UC and Crohn’s disease; more than
90% of the patients used it. This is significantly more
frequent than in the recent report by Hyams et al. (60%) on
early drug use, which focuses on the use of thiopurines for
patients with pediatric UC [23]. The incidence of UC in Fin-
land is far more common that of Crohn’s disease and, as with
most pediatric patients, Crohn’s disease most often aﬀects
the colon or ileocolon [4, 8]. Therefore, it is not surprising
that patients with Crohn’s disease also frequently use 5-ASA,
although the evidence shows that the overall benefits are
weak [10, 12]. Patients with UC used systemic 5-ASA therapy
more towards the end of the study period: 97% of them did
so by the end of the study. This may reflect the high number
of patients with pancolitis [8].
In line with recent reports (based on chart review),
doctors often prescribe corticoids after first diagnosing IBD.
Here, three out of four patients purchased corticoids within
the first three months. This is in line with a recent report
from Denmark [24] and previously published reports from
the IBD registry [25, 26]. During the eleven-year period,
there was no significant change in the proportion of patients
receiving corticoids, and the figures were comparable
between Crohn’s disease and UC. Thus, it is unlikely that
there has been any significant change in the disease pheno-
type and severity at one year after diagnosis, although the
incidence of pediatric IBD has dramatically increased [3, 4].
There is no guideline yet for introducing azathioprine
to patients in the early stages of Crohn’s disease, although
it is agreed that extensive disease or severe growth failure
is an indication of active immunosuppression during the
initial course of the disease [10]. With UC, there are no
guidelines for azathioprine use in pediatric patients. An
increase in the use of immunomodulators for pediatric IBD
from 1990 to 2000 was reported in a questionnaire survey
of pediatric gastroenterologists, although the response rate
was disappointingly only 39% [27] There was a significant
increase in the use of azathioprine during the study period
and, by the end of the study period, up to 50% of patients
with Crohn’s disease purchased azathioprine within the first
year. In comparison, this therapy was introduced signifi-
cantly earlier in the years 2008-2009, when the mean time
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Table 4: Background data related to the systemic drug therapy strategies during the first 6 months of pediatric inflammatory bowel disease
(n = 471 patients).
Single Combinations
Variable 5-ASA 5-ASA + corticosteroid Azathioprinea P value
n = 131 n = 217 n = 123
Gender (male), n (%) 79 (60.3) 116 (53.5) 71 (57.7) 0.435
Age at IBD diagnosis, mean (SD) 7.5 (3.8) 8.6 (3.9) 9.4 (3.8) <0.001
Subtype (diagnosis of Crohn’s disease), n (%) 45 (34.4) 71 (32.7) 66 (53.6) <0.001
Time period (years 2008-2009), n (%) 38 (29.0) 92 (42.4) 63 (51.2) 0.002
aWith other medications (e.g., 5-ASA or/and corticosteroid).
from the diagnosis to the introduction of azathioprine was
approximately three months. There were no such changes for
patients with UC, and by the end of the study approximately
every third patient was using azathioprine. Of the other
immunomodulators, the numbers of purchases were low.
Gender had no eﬀect on the treatment strategies, but
the use of azathioprine was less frequent in younger patients
than in older patients. This may reflect a fear of the side
eﬀects of azathioprine or the prolonged use of corticoids. The
use of corticoids did not, however, vary according to age.
Importantly, although the use of azathioprine significantly
increased during this decade, it did not prevent patients from
using other therapeutic agents during the first year of diag-
nosis.
4.1. Strengths and Limitations. The main strength of this
study was the use of comprehensive nationwide, register-
based data on drugs dispensed at pharmacies [28]. Whereas,
by focusing on purchases as a monitor of patient drug use,
we could not assess patient non-compliance, but in a study
like ours there is no recall bias and the data suggest a better
correspondence to real use than data based on chart reviews
or prescriptions [29]. The disease severity or the clinical dis-
ease activity could not be assessed. The focus, however, was
on therapeutic strategies and possible changes during the
study period rather than on individual therapeutic responses.
Furthermore, 98% of the IBD cases in the Finnish Drug
Reimbursement Register met modern diagnostic criteria,
indicating excellent specificity [4]. All diagnoses were based
on written certificates, including the diagnostic criteria, and
checked by Kela. Thus, the possibility of misdiagnoses is low.
The results of corticosteroid use were somewhat hampered
by the fact that 5mg tablets of prednisolone are not reim-
bursed in Finland during the years 2006-2007 and, thus, such
purchases were not registered. This is unlikely to cause a
major bias because the proportion of corticoid use remained
fairly constant.
As a limitation, we could not assess the nationwide use
of infliximab, which is licensed for use in pediatric Crohn’s
disease in children older than six years of age. There were,
however, no patients without medication during the first six
months after diagnosis, and, during the latter part of the
year, patients with no medication were an exception. Thus,
the use of infliximab occurs in combination with the more
conventional medication and that, evidently, patients solely
on infliximab therapy were rare during the first year of diag-
nosis. This is supported by data gathered for this time period
in our hospital, which show that between 2005 and 2010,
only 11% of pediatric patients were on infliximab during
their first year of diagnosis, and single therapy with inflix-
imab was the exception. Elsewhere in Finland, the total use of
infliximab has been less frequent (K.-L. Kolho, unpublished
data).
In conclusion, there is limited data on strategies of drug
therapy in pediatric IBD. This study demonstrates a high use
of corticoids in pediatric Crohn’s disease and UC at the time
of diagnosis. During the last decade, the therapeutic strategy
of Crohn’s disease has shifted towards more active use and
azathioprine is introduced earlier. So far, the use of bio-
logicals is not reflected in therapeutic strategies for patients
during the first year of pediatric Crohn’s disease.Whether the
increased use of immunosuppressants is eﬃcient in reducing
the high surgery rates of pediatric IBD patients needs to be
assessed in the future.
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